We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.16B
1-Year Est. Return 67.93%
This Fund
S&P 500
This Quarter Est. Return
+43.07%
1 Year Est. Return
+67.93%
3 Year Est. Return
-39.17%
5 Year Est. Return
-45.89%
10 Year Est. Return
–
AUM
$9.55B
AUM Growth
+$1.72B
Cap. Flow
-$610M
Cap. Flow %
-6.38%
Top 10 Hldgs %
99.02%
Holding
13
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
OMGA
Omega Therapeutics, Inc. Common Stock
OMGA
+$497M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$1.11B

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$21.5B
$6.77B 70.86%
17,581,016
-3,000,000
-15% -$1.11B
SANA icon
2
Sana Biotechnology
SANA
$885M
$771M 8.07%
34,239,018
– –
RUBY
3
DELISTED
Rubius Therapeutics, Inc
RUBY
$688M 7.21%
38,506,526
– –
OMGA
4
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$488M 5.11%
+25,902,269
New +$497M
FHTX icon
5
Foghorn Therapeutics
FHTX
$285M
$177M 1.85%
12,674,120
– –
EVLO
6
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$162M 1.7%
1,151,503
– –
DNLI icon
7
Denali Therapeutics
DNLI
$3.67B
$138M 1.44%
2,730,263
– –
KLDO
8
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$107M 1.12%
19,575,710
– –
MCRB icon
9
Seres Therapeutics
MCRB
$48.1M
$100M 1.05%
718,940
– –
SGTX
10
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$58.6M 0.61%
797,721
– –
CDAK
11
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$42.6M 0.45%
2,607,303
– –
AXLA
12
DELISTED
Axcella Health Inc. Common Stock
AXLA
$37.4M 0.39%
501,937
– –
SYRS
13
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$13.1M 0.14%
293,849
– –

Similar funds

AC
AltraVue Capital Bellevue, Washington $1.16B AUM 46.45% 1-Year Est. Return
BI
Bramshill Investments Naples, Florida $1.16B AUM 0.86% 1-Year Est. Return
SCP
Sandhill Capital Partners Buffalo, New York $1.16B AUM 12.37% 1-Year Est. Return
SFG
SNS Financial Group Minneapolis, Minnesota $1.16B AUM 13.88% 1-Year Est. Return
GAB
German American Bancorp Jasper, Indiana $1.16B AUM 25.7% 1-Year Est. Return
AMI
Amica Mutual Insurance Providence, Rhode Island $1.16B AUM 21.34% 1-Year Est. Return
FFP
FourThought Financial Partners Venice, Florida $1.16B AUM 24.95% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Flagship Pioneering's Q3 2021 Portfolio in Review

As of Q3 2021, Flagship Pioneering held 13 positions worth $9.55B, up 22% from $7.83B the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Flagship Pioneering withdrew a net $610M in Q3 2021, reducing 1 holding. Its largest reduction was Moderna, cutting an estimated $1.11B.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Flagship Pioneering opened a new position in Omega Therapeutics, Inc. Common Stock worth $488M.

  • Flagship Pioneering's largest Q3 2021 buy was Omega Therapeutics, Inc. Common Stock: 25,902,269 shares worth $488M.
  • Flagship Pioneering's biggest Q3 2021 reduction was Moderna, cutting an estimated $1.11B.
  • Flagship Pioneering's ten largest holdings make up 99% of its $9.55B portfolio in Q3 2021.
  • Flagship Pioneering opened 1 new position and closed 0 in Q3 2021.
  • Flagship Pioneering's portfolio value rose 22% quarter-over-quarter to $9.55B.

Based on Flagship Pioneering's 13F filing for Q3 2021, filed 15 Nov 2021.